Published in:
Open Access
01-12-2014 | Research
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
Authors:
B Douglas Smith, Charles L Beach, Dalia Mahmoud, Laura Weber, Henry J Henk
Published in:
Experimental Hematology & Oncology
|
Issue 1/2014
Login to get access
Abstract
Background
This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment.
Methods
A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012.
Results
Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine.
Conclusions
This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.